Evidence map›Paper›PMID 33420491›Full record

ArticleNature cell biology2021

Evaluating totipotency using criteria of increasing stringency.

Eszter Posfai, John Paul Schell, Adrian Janiszewski, Isidora Rovic, Alexander Murray, Brian Bradshaw, Tatsuya Yamakawa, Tine Pardon, Mouna El Bakkali, Irene Talon and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed.

  1. Article
  2. The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Developing stem cell-based bovine embryos for in vitro breeding.The Journal of reproduction and development · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Totipotency or plenipotency: rethinking stem cell bipotentiality.Current opinion in genetics & development · 2025
    Review
  20. Review

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eszter Posfai *Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada. eposfai@princeton.edu.ORCID http://orcid.org/0000-0002-4871-6652
John Paul Schell *Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Adrian Janiszewski *Department of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.
Isidora RovicLunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Alexander MurrayProgram in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
Brian BradshawProgram in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
Tatsuya YamakawaProgram in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
Tine PardonDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.
Mouna El BakkaliDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.
Irene TalonDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.
Natalie De GeestDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.
Pankaj KumarDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8411-1634
San Kit ToDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3057-2902
Sophie PetropoulosDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Andrea JurisicovaLunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Vincent PasqueDepartment of Development and Regeneration, Leuven Stem Cell Institute, KU Leuven, Leuven, Belgium. vincent.pasque@kuleuven.be.ORCID http://orcid.org/0000-0002-5129-0146
Fredrik LannerDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. fredrik.lanner@ki.se.ORCID http://orcid.org/0000-0002-2771-7445
Janet RossantProgram in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada. janet.rossant@sickkids.ca.ORCID http://orcid.org/0000-0002-3731-5466

Funding

CIHR FDN-143334
6 · The paper itself

Abstract

Totipotency is the ability of a single cell to give rise to all of the differentiated cell types that build the conceptus, yet how to capture this property in vitro remains incompletely understood. Defining totipotency relies on a variety of assays of variable stringency. Here, we describe criteria to define totipotency. We explain how distinct criteria of increasing stringency can be used to judge totipotency by evaluating candidate totipotent cell types in mice, including early blastomeres and expanded or extended pluripotent stem cells. Our data challenge the notion that expanded or extended pluripotent states harbour increased totipotent potential relative to conventional embryonic stem cells under in vitro and in vivo conditions.

Indexed as

Cell DifferentiationAnimalsBlastomeresCell LineageEmbryo, MammalianEmbryonic Stem CellsFemaleGene Expression ProfilingGene Regulatory NetworksMaleMicePluripotent Stem CellsSingle-Cell AnalysisTotipotent Stem Cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.